Jo Ann Leal, PharmD (Twitter: @jojopharmd) describes the implications of various CYP2C19 phenotypes on clopidogrel metabolism and activity, analyzes the available literature evaluating outcomes of clopidogrel versus ticagrelor in ischemic stroke patients based on CYP2C19 metabolizer status and selects a preferred antiplatelet agent and dose for secondary prevention of ischemic stroke given patient specific pharmacogenomic information.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.